engleski

Dijabetički makularni edem: tradicionalni I novi pristup liječenju

Diabetes is one of the leading public health problems worldwide. Diabetic macular edema (DME) is the main cause of vision loss in patients with diabetes. Ideal metabolic control of diabetes is the primary goal of treatment and basic way of preventing and stopping the progression of DME. Although laser photocoagulation has been the standard treatment of DME for nearly three decades, superior outcomes can be achieved with novel, intravitreal anti-VEGF and steroid, therapy. Novel treatment option of DME depends on visual acuity and location/extent of macular thickening based on OCT scans. According to the International Clinical Classification Scale DME is divided into no center-involving DME and center-involving DME (CI-DME). New guidelines recommend intravitreal treatment as a treatment of choice for patients with CI-DME and moderate visual impairment. Patients with no CI-DME and mild visual impairment should be treated with a modified ETDRS laser photocoagulation and closely observed. Vitrectomy is a treatment of choice for patients with a tractional component of DME. Nowadays traditional treatment goal of preventing blindness in patients with DME is changed in novel goal aimed to restore impaired vision, prevent further vision loss and improve visual function ; therefore many trials worldwide are already running to address this.

Dijabetički makularni edem ; Laserska fotokoagulacija ; Intravitrealno liječenje

nije evidentirano